72 related articles for article (PubMed ID: 9403222)
1. Amlodipine has a minor effect on cyclosporine metabolism.
McGregor DO; Bailey RR; Robson RA
Clin Nephrol; 1997 Nov; 48(5):336. PubMed ID: 9403222
[No Abstract] [Full Text] [Related]
2. Prediction of cyclosporine clearance in liver transplant recipients by the use of midazolam as a cytochrome P450 3A probe.
Villeneuve JP; L'Ecuyer L; De Maeght S; Bannon P
Clin Pharmacol Ther; 2000 Mar; 67(3):242-8. PubMed ID: 10741627
[TBL] [Abstract][Full Text] [Related]
3. Early postoperative erythromycin breath test correlates with hepatic cytochrome P4503A activity in liver transplant recipients.
Schmidt LE; Olsen AK; Stentoft K; Rasmussen A; Kirkegaard P; Dalhoff K
Clin Pharmacol Ther; 2001 Nov; 70(5):446-54. PubMed ID: 11719731
[TBL] [Abstract][Full Text] [Related]
4. Genetics. SNP-ing drugs to size.
Gura T
Science; 2001 Jul; 293(5530):595. PubMed ID: 11474082
[No Abstract] [Full Text] [Related]
5. Role of human CYP3A and P-glycoprotein on the absorption of drugs.
van de Waterbeemd H
Eur J Pharm Sci; 2000 Nov; 12(1):1. PubMed ID: 11121728
[No Abstract] [Full Text] [Related]
6. Erythromycin breath test.
Watkins PB
Clin Pharmacol Ther; 2000 May; 67(5):577-8. PubMed ID: 10824637
[No Abstract] [Full Text] [Related]
7. P450IIIA (CYP3A) activity in severely depressed patients.
Watkins PB; Turgeon DK; Guthrie SK; Remen AL; Grunhaus L
J Clin Psychopharmacol; 1993 Oct; 13(5):366-8. PubMed ID: 8227499
[No Abstract] [Full Text] [Related]
8. Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects.
Dresser GK; Schwarz UI; Wilkinson GR; Kim RB
Clin Pharmacol Ther; 2003 Jan; 73(1):41-50. PubMed ID: 12545142
[TBL] [Abstract][Full Text] [Related]
9. Thin-layer chromatographic analysis of human CYP3A-catalyzed testosterone 6 beta-hydroxylation.
Waxman DJ; Chang TK
Methods Mol Biol; 1998; 107():153-61. PubMed ID: 14577225
[No Abstract] [Full Text] [Related]
10. Use of the erythromycin breath test for in vivo assessments of cytochrome P4503A activity and dosage individualization.
Chiou WL; Jeong HY; Wu TC; Ma C
Clin Pharmacol Ther; 2001 Oct; 70(4):305-10. PubMed ID: 11673745
[No Abstract] [Full Text] [Related]
11. CYP3A genetics in drug metabolism.
Eichelbaum M; Burk O
Nat Med; 2001 Mar; 7(3):285-7. PubMed ID: 11231620
[No Abstract] [Full Text] [Related]
12. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole.
Tsunoda SM; Velez RL; von Moltke LL; Greenblatt DJ
Clin Pharmacol Ther; 1999 Nov; 66(5):461-71. PubMed ID: 10579473
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic interaction of cytochrome P450 3A-related compounds with rhodamine 123, a P-glycoprotein substrate, in rats pretreated with dexamethasone.
Yumoto R; Murakami T; Sanemasa M; Nasu R; Nagai J; Takano M
Drug Metab Dispos; 2001 Feb; 29(2):145-51. PubMed ID: 11159804
[TBL] [Abstract][Full Text] [Related]
14. Grapefruits and drugs: when is statistically significant clinically significant?
Abernethy DR
J Clin Invest; 1997 May; 99(10):2297-8. PubMed ID: 9153265
[No Abstract] [Full Text] [Related]
15. Cisapride (Prepulsid): interactions with grapefruit and drugs.
Morawiecka I
CMAJ; 2000 Jan; 162(1):105-6, 109-10. PubMed ID: 11216183
[No Abstract] [Full Text] [Related]
16. Effects of disease on expression and regulation of CYPs.
Farrell G
Mol Aspects Med; 1999; 20(1-2):55-70, 137. PubMed ID: 10575652
[No Abstract] [Full Text] [Related]
17. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism: the effect of assay conditions and regioselective stimulation by alpha-naphthoflavone, terfenadine and testosterone.
Mäenpää J; Hall SD; Ring BJ; Strom SC; Wrighton SA
Pharmacogenetics; 1998 Apr; 8(2):137-55. PubMed ID: 10022752
[TBL] [Abstract][Full Text] [Related]
18. The aromatase inactivator 4-hydroxyandrostenedione (4-OH-A) inhibits tamoxifen metabolism by rat hepatic cytochrome P-450 3A: potential for drug-drug interaction of tamoxifen and 4-OH-A in combined anti-breast cancer therapy.
Dehal SS; Brodie AM; Kupfer D
Drug Metab Dispos; 1999 Mar; 27(3):389-94. PubMed ID: 10064571
[TBL] [Abstract][Full Text] [Related]
19. Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer: implications for drug therapy.
Martínez C; García-Martín E; Pizarro RM; García-Gamito FJ; Agúndez JA
Br J Cancer; 2002 Sep; 87(6):681-6. PubMed ID: 12237780
[TBL] [Abstract][Full Text] [Related]
20. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts.
Chalasani N; Gorski JC; Patel NH; Hall SD; Galinsky RE
Hepatology; 2001 Dec; 34(6):1103-8. PubMed ID: 11731998
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]